Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026)
Atea Pharmaceuticals (AVIR) recorded quarterly Cash from Financing Activities of $257000.0 in Q1 2026, up 102.27% quarter-over-quarter from -$11.3 million in Q3 2025, and up 174.06% on a YoY basis from $93773.9 in Q1 2025.
Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $257000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 174.06% year-over-year to $257000.0; the TTM figure through Mar 2026 stood at -$25.1 million (down 10830.87% YoY), while the FY2025 annual figure was -$25.7 million, down 9742.32% from the prior year.
- Cash from Financing Activities was $257000.0 for Q1 2026 at Atea Pharmaceuticals, up from -$11.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $257000.0 in Q1 2026 to a low of -$14.1 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged -$2.5 million across 5 years, with a median of $132000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 9762.39% in 2025, then jumped 174.06% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $147000.0 in 2022, then sank by 37.41% to $92000.0 in 2023, then rose by 27.17% to $117000.0 in 2024, then slumped by 9762.39% to -$11.3 million in 2025, then jumped by 102.27% to $257000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $257000.0 (Q1 2026), -$11.3 million (Q3 2025), and -$14.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | 257,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257,000.00 |
| Mar 31, 2026 | 257,000.00 |
| Sep 30, 2025 | -11.31 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Jun 30, 2025 | -14.09 Mn |
| Mar 31, 2025 | -347,000.00 |
| Mar 31, 2025 | -347,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Sep 30, 2022 | 147,000.00 |
| Sep 30, 2022 | 147,000.00 |
| Mar 31, 2022 | 223,000.00 |
| Mar 31, 2022 | 223,000.00 |